Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.


TSX:SZLS - Post by User

Comment by Melrayon Jul 01, 2021 3:15pm
96 Views
Post# 33479823

RE:RE:Results

RE:RE:Results
regardless of the participation level, those who did vote, voted 44% to withheld. Meaning they didn't support Tripp. Using your 12.5 as a bases, that means 5.5m votes to abstain. Now assuming the insiders pooled thier votes which combined are alot (sorry don't have exact # handy) it is not unreasonable to assume Tripp did not receive very much support from outside the slate. I won't disagree with your point that a large institutional investor such as Clarus or Echelon can significantly impact the numbers, especially with low 20% participation rate. But, I have to wonder why? To what end? If they want to have an impacted on the Board or share prices, me thinks there are better ways.
<< Previous
Bullboard Posts
Next >>